New Influenza Vaccine Options Introduced in South Korea, Promising Enhanced Immunity and Economic Benefits
Seoul, South Korea – South korea is set too see the introduction of new influenza vaccine options, including a cell-culture-based vaccine and an adjuvanted vaccine, offering possibly enhanced protection and economic advantages, especially for the elderly. The vaccines, developed by CSL Seqirus, were highlighted at a press conference in Seoul, where medical experts discussed thier benefits.
professor Roh Ji-yoon of Infectious medicine at Korea University guro Hospital emphasized that the new vaccines go beyond simply preventing infection, citing a reduction in hospitalization rates due to influenza. One of the featured vaccines, “Fluad Quad,” incorporates MF59 adjuvant technology, which is designed to stimulate a stronger and longer-lasting immune response in individuals aged 65 and older. CSL Seqirus highlighted the economic advantages of Fluad Quad, presenting an economic analysis for South Korea and Taiwan. This analysis indicated that the vaccine could prevent a significant number of influenza cases, hospitalizations, and deaths, while also reducing social costs associated with illness, such as nursing care, transportation, and lost productivity.
professor Choi Min-joo, also from Infectious Medicine at Korea University Guro Hospital, supported the transition to immune-enhanced vaccines, stating it is a “reasonable choice” from both medical and economic perspectives.
The cell-culture-based influenza vaccine, “Flucelvax Quad,” is slated for release in South Korea ahead of the 2025/26 influenza season. CSL Seqirus has partnered with Strikeout Pharmaceuticals for its domestic distribution. Flucelvax Quad has already received approval from the Ministry of Food and Drug Safety for use in children and adults aged two years and older.
The CEO of CSL Seqirus Korea expressed enthusiasm about providing “differentiated options” in the influenza prevention landscape, noting the existing demand. the company plans to collaborate closely with healthcare professionals, researchers, and health authorities to ensure wider access to these innovative vaccines.
